跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 5,426 条关于
“NASDAQ: RNXT”
全部
5,426
临床试验
2,860
药物
43
机构
17
资讯
2,506
去年
RenovoRx Secures $12.1M Through Public Offering to Advance Pancreatic Cancer Trial
去年
RenovoRx Boosts RenovoCath Production Amid Rising Demand for Targeted Oncology Therapies
去年
RenovoRx Announces Investor Fireside Chat and Provides Update on TIGeR-PaC Trial
去年
RenovoRx Secures New U.S. Patent for TAMP Therapy Platform, Strengthening IP Portfolio for Targeted Cancer Treatment
去年
RenovoRx Launches Multi-Center PanTheR Registry Study to Evaluate Real-World Safety of RenovoCath Device
去年
RenovoRx Reports Strong Q2 2025 Commercial Growth and Positive Phase III Trial Continuation
去年
Psyence Biomed Expands Phase IIb Psilocybin Trial for Adjustment Disorder in Palliative Care
2年前
Lixte Biotechnology Faces Nasdaq Delisting Over Equity Shortfall, Plans Compliance Measures
去年
Revelation Biosciences Receives Nasdaq Continued Listing Approval, Advances Gemini Program
3个月前
PDS Biotechnology Regains Nasdaq Compliance After Minimum Bid Price Deficiency
第 1 页,共 251 页
上一页
下一页